Orchid Pharma Completes Amalgamation of Dhanuka Laboratories, Announces New Capital Structure and Share Exchange Ratio

Orchid Pharma Completes Amalgamation of Dhanuka Laboratories, Announces New Capital Structure and Share Exchange Ratio​

Orchid Pharma Limited has announced that its scheme involving the amalgamation of Dhanuka Laboratories Limited is now effective, resulting in the dissolution of the latter company without being wound up.

The Board of Directors of Orchid Pharma Limited confirmed that the Scheme became operational on July 10, 2026, having met all prescribed conditions. The Amalgamating Company, Dhanuka Laboratories Limited (DLL), holds an appointed date of April 1, 2024.

Following the effectiveness of the Scheme, the authorized share capital of Orchid Pharma Limited was automatically increased due to the transfer and amalgamation of DLL’s authorised capital with that of Orchid Pharma Limited. The Memorandum of Association (MoA) of Orchid Pharma Limited now reflects a new authorized share capital structure.

The Company's authorized share capital is set at Rs. 164,51,00,000, which is divided into 16,45,10,000 equity shares with a face value of Rs. 10 each.

In relation to the completion of the amalgamation, Orchid Pharma Limited also determined the record date for determining the shareholders of Dhanuka Laboratories who would be issued shares in the amalgamated company. The record date is set as Thursday, July 23, 2026.

The Scheme established a specific share exchange ratio governing the transaction. Members of the Amalgamating Company (Dhanuka Laboratories Limited) will be allotted 161 fully paid up equity shares of Orchid Pharma Limited against every 5 fully paid up equity shares they hold in Dhanuka Laboratories Limited.

ORCHPHARMA Stock Price Movement​

Shares of Orchid Pharma Limited today slipped by 4.09% to settle at ₹1012.55, following the late-day trading session. The stock saw a volume of 288,100 shares traded in total.